FDA Approves Jetrea for Sight-Threatening Symptomatic Vitreomacular Eye Adhesions

The FDA approved Jetrea (ocriplasmin), the first drug approved to treat a sight-threatening eye condition called symptomatic vitreomacular adhesion (VMA). VMA can contribute to eye problems if the vitreous (jelly in the center of the eye) starts to move away from the macula (a part of the retina responsible for reading vision). This movement can lead to damage of the macula due to pulling or tugging on the macula.


Jetrea is an enzyme that breaks down proteins in the eye responsible for VMA. The breakdown of these proteins allows a better separation between the vitreous and macula and can reduce the chances that tugging will occur. The alternative treatment for this condition is a surgical procedure called a vitrectomy. Jetrea is the first non-surgical treatment option for VMA.


The most common side effects reported in patients treated with Jetrea include eye floaters; bleeding of the conjunctiva, the tissue that lines the inside of the eyelids and covers the white part of the eye; eye pain; flashes of light (photopsia); blurred vision; unclear vision; vision loss; retinal edema (swelling); and macular edema.


See the FDA Announcement